AGTX 最新10-K变化
将 AGTX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-K · 2026-07-01 与上一份 10-K · 2025-07-16
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 业务概况 | 文字有新增/删除 | 0 | 0 | ~2 | 41 |
| 风险因素 | 无段落级文字变化 | 0 | 0 | 0 | 5 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 管理层讨论与分析 | 文字有新增/删除 | +8 | −10 | ~2 | 6 |
| 市场风险(第7A项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-K · 2026-07-01
For the year ended March 31, 2026, we incurred total research and development expenses of $125,079 as compared to $180,987 for our year ended March 31, 2025, a decrease of $55,908. The decrease was mainly related to an increase in R&D consulting, offset by a decrease in supplies and materials and pa…
For the year ended March 31, 2026, general and administrative expenses were $68,072 as compared to $69,898 for our year ended March 31, 2025, a decrease of $1,826.
For the year ended March 31, 2026, foreign exchange gain was $24,584 as compared to foreign exchange loss of $11,128 for the year ended March 31, 2025.
For the year ended March 31, 2026, cash used from our operating activities was $108,529 of cash as compared to a use of cash of $125,078 during the year ended March 31, 2025.
For the year ended March 31, 2026, cash from financing was $110,450 versus $100,000 for our year ended March 31, 2025. Cash from financings during the year ended March 31, 2026 and 2025, respectively, consisted of $110,450 and $100,000 from loan proceeds received.
相对上期删除的文字 · 来源:10-K · 2025-07-16
For the year ended March 31, 2025, professional fees were $262,366 as compared to $222,999 for the year ended March 31, 2024, an increase of $39,367. The Increase in professional fees mainly to an increase in accounting and consulting fees.
For the year ended March 31, 2025, we incurred total research and development expenses of $180,987 as compared to $175,268 for our year ended March 31, 2024, an increase of $5,719. The increase was mainly related to increase in R&D consulting costs.
For the year ended March 31, 2025, general and administrative expenses were $69,898 as compared to $346,543 for our year ended March 31, 2024, a decrease of $276,645. The decrease was mainly related to a decrease in royalty fee we incurred related to patents in the prior period, compared to the prio…
For the year ended March 31, 2025 and 2024, we received R&D credits totaling $0 and $198,371 related to our R&D efforts that occurred at our Agentix Australia Pty Ltd entity. We did not receive any R&D credits for the comparable period ended March 31, 2025.
For the year ended March 31, 2025, cash used from our operating activities was $125,078 of cash as compared to a use of cash of $110,429 during the year ended March 31, 2024.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议